Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xtandi | Enzalutamide | First Line Metastatic Castration-Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xtandi | Enzalutamide | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xtandi | Enzalutamide | mHSPC | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | enzalutamide | Genito-urinary cancer (prostate cancer) | Open for Stakeholder Input | |||
| Rozlytrek | entrectinib | Extracranial solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBD | Entrectinib | Withdrawn | ||||
| Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Baraclude | Entecavir | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | ||
| Padcev | enfortumab vedotin | Metastatic urothelial cancer | Pending | |||
| Padcev | enfortumab vedotin | Locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 16, 2024